M. Michele Blackwood was named chief of breast surgery at Rutgers Cancer Institute of New Jersey.
Subha Madhavan was named chief data scientist and director of its new Office for Health Data Science and Informatics at Georgetown University Medical Center.
AbbVie announced a donation of $5 million to Family Reach to support the organization's efforts to alleviate the financial burden of cancer on pediatric patients and families across the United States.
Six new health systems have committed to sharing data upon joining the Syapse Learning Health Network: Ascension, Banner Health, Inova Health, LSU Health, OhioHealth, and Seoul National University Hospital.
As residents across the southeastern United States face the early impact of Hurricane Florence, CancerCare prepares to offer emotional and financial support to cancer patients impacted by the storm.
The U.S. Senate Sept. 18 passed a conference “minibus” appropriations package that will increase the NIH budget by $2 billion to $39.1 billion—a 5.4 percent boost over the current level.
José Baselga, who has resigned from his positions as physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center, is winding down his research and clinical activities at that institution, officials said.
The European Commission has approved the Novartis agent Kymriah (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse post-transplant or in second or later relapse; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Bristol-Myers Squibb Co. said FDA accepted its supplemental Biologics License Application for Empliciti (elotuzumab) in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
Rafael Pharmaceuticals Inc. said FDA has granted an orphan drug designation to CPI-613, the company's lead Altered Energy Metabolism Directed drug candidate, for the treatment of peripheral T-cell lymphoma.
